key: cord-0747655-twtlooqo
authors: SPACONE, ANTONELLA; Esposito, Antonietta; Zuccarini, Giacomo; Prosperi, Pierpaolo; Rapacchiale, Giorgia; Di Lorito, Alessandra; Zara, Benedetta; D'Apolito, Alessandro; Barone, Adriano; Rampino, Ilaria; De Palma, Antonio; di fabio, natasha; Maria Di Flamminio, Filippo; Basilisco, Matteo; Bondanese, Martina; Frattari, Antonella; Parruti, Giustino
title: THE UTILITY OF EARLY HIGH FLOW NASAL OXYGEN THERAPY (FROM ER TO DISCHARGE AND HOME) IN PATIENT WITH SEVERE COVID-19 PNEUMONIA
date: 2021-10-31
journal: Chest
DOI: 10.1016/j.chest.2021.07.1519
sha: 9ae8c520bc28d7be0ddb804a2fdbef7f384e59e4
doc_id: 747655
cord_uid: twtlooqo

nan

. HFNO, delivering adequately heated and humidified medical gas at flow-rates of up to 60 L/min, is considered to have a number of benefits: it facilitates removal of airway secretions, decreases work of breathing, improves ventilation and oxygen delivery, including the reduction of the anatomical dead space, facilitates respiratory/bronchial physiotherapy and muscle rehabilitation, provides a constant fraction of inspired oxygen with adequate humidification and a relevant degree of positive end-expiratory pressure (PEEP), to keep alveoli open (2).It is not adequately known, however, is when to resort on this kind of treatment, to get the most prominent benefits.

A 55-year-old female with SARS-COV2 infection and a history of Rheumatoid Arthritis of recent onset was admitted to our hospital after 7 days of fever. In the Emergency Room, a chest HRCT scan was performed ( fig.1) , showing bilateral diffuse ground glass opacities; her blood gas analysis (ABG) was: pH 7.51, PaCO2 35mmHg, PaO2 59mmHg, HCO3À 24mmol/L, PaO2/FiO2 280; her respiratory rate (RR) was 25/min. In spite of clinically relevant features, an early HFNO delivery trial was attempted. Initial temperature, inspired oxygen fraction (FiO2) and flow rate were 34 C, 40L/min and 60% respectively. ROX index, defined as the ratio of pulse oximetry/fraction of inspired oxygen to RR was monitored (3). Laboratory tests showed mild lymphopenia, (700/mm3); C-reactive protein 35 mg/L; normal procalcitonin, LDH 385 U/L, D dimer 1.27 mg/L. She was treated with subcutaneous Tocilizumab (324 mg), single shot, steroids (methyl-prednisolone 40 mg/daily), EBPM, azithromycin (500 mg/daily) for 10 days. The patient was discharged after 10 days, ABG in room air was: pH 7.43, PaCO2 35mmHg, PaO2 65mmHg, HCO3À 23mmol/L, PaO2/FiO2 309, with indication to continue HFNO at home during the night, with a low dose of steroid for 6 additional days. A control CT scan after 1 month from discharge showed a near-complete reduction of lung opacities ( fig. 2) .

Our experience with an adult woman with moderate respiratory distress, started early with HFNO since ER, shows that her marked improvement of gas exchange and ventilatory function with HFNO may be partly related to such an early administration of HFNO. This treatment could be continued at home for 30 days after discharge, helping in her fast resolution of the alveolar infiltrates.

CONCLUSIONS: Randomized controlled trials are needed, to explore the pivotal idea that early administration and long resorting on HFNO may enhance both the benefits and the long-term duration of respiratory function recovery after SARS-CoV2 acute pneumonia.

High-flow nasal oxygen: a safe, efficient treatment for COVID-19 patients not in an ICU

High-flow nasal cannula oxygen therapy in adultsJ Intensive Care

High-flow, noninvasive ventilation and awake (nonintubation) proning inpatients with Coronavirus Disease 2019 with respiratory failure